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Expression of the oncogenic transcription factor MYC is disproportionately elevated in triple-negative breast cancer (TNBC), as compared to estrogen receptor-, progesterone receptor-or human epidermal growth factor 2 receptorpositive (RP) breast cancer 1, 2 . We and others have shown that MYC alters metabolism during tumorigenesis 3, 4 . However, the role of MYC in TNBC metabolism remains mostly unexplored. We hypothesized that MYC-dependent metabolic dysregulation is essential for the growth of MYC-overexpressing TNBC cells and may identify new therapeutic targets for this clinically challenging subset of breast cancer. Using a targeted metabolomics approach, we identified fatty acid oxidation (FAO) intermediates as being dramatically upregulated in a MYC-driven model of TNBC. We also identified a lipid metabolism gene signature in patients with TNBC that were identified from The Cancer Genome Atlas database and from multiple other clinical data sets, implicating FAO as a dysregulated pathway that is critical for TNBC cell metabolism. We found that pharmacologic inhibition of FAO catastrophically decreased energy metabolism in MYC-overexpressing TNBC cells and blocked tumor growth in a MYC-driven transgenic TNBC model and in a MYC-overexpressing TNBC patientderived xenograft. These findings demonstrate that MYC-overexpressing TNBC shows an increased bioenergetic reliance on FAO and identify the inhibition of FAO as a potential therapeutic strategy for this subset of breast cancer.
We hypothesized that MYC-dependent metabolic dysregulation is essential for MYC-overexpressing TNBC. To test this hypothesis, we investigated tumor metabolism in a conditional doxycycline-inducible transgenic model of MYC-overexpressing TNBC (MTB-TOM) 5, 6 . We used mass spectrometry to compare the global metabolic profile of MTB-TOM tumors to that of naive mammary glands from MTB-TOM transgenic mice in which MYC was not induced. Metabolite analysis revealed a number of dysregulated pathways in MTB-TOM tumors that are commonly associated with tumorigenesis-including glycolysis, the tricarboxylic acid (TCA) cycle and fatty acid metabolism ( Fig. 1a,  Supplementary Fig. 1 and Supplementary Table 1 ). Although fatty acid synthesis (FAS) is upregulated in many types of cancer, a MYCdependent role for FAO in breast tumorigenesis has not previously been described 4, 7, 8 . Considering the proximity of primary breast tumors to the adipose-rich mammary gland, we chose to focus on the dysregulation of FAO in MYC-overexpressing TNBC cells.
To investigate the role of MYC in FAO upregulation in TNBC cells, we returned to our MTB-TOM metabolomic data ( Supplementary  Table 1 ). Acylcarnitines are an essential intermediate and are involved in the first committed step of FAO 9 . To catabolize long-chain fatty acids (such as palmitate) to acetyl-coenzyme A (acetyl-CoA), a major fuel for biosynthetic and bioenergetic metabolism, acyl-CoAs must be enzymatically converted to acylcarnitines across the outer mitochondrial membrane by carnitine palmitoyltransferase 1 (CPT1A or CPT1B) 9 . We found that all six acylcarnitine intermediates detected in our metabolomic analysis were significantly elevated in MTB-TOM tumors than in control tissue ( Fig. 1b) . To further validate these steady-state findings in vivo, we assayed acylcarnitine production in MTB-TOM tumors 4 h after intraperitoneal (i.p.) injection of [ 13 C]palmitate into tumor-bearing mice. Tumor tissue had a fourfold increase in [ 13 C]palmitoyl-carnitine production, as compared to that in control mammary gland tissue (Fig. 1c) . Because [ 13 C]palmitoylcarnitine production was not normalized to overall uptake in this experiment, this increase could reflect a relative increase in fatty acid uptake, fatty acid utilization via oxidation or both. Nevertheless, taken together, these data indicate that the first committed step of FAO is upregulated in MYC-overexpressing TNBC cells.
To determine how FAO is altered in TNBC, we analyzed RNA expression data from primary human tumors (771 patient samples from The Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer l e t t e r s 4 2 8 VOLUME 22 | NUMBER 4 | APRIL 2016 nature medicine Cancer Genome Atlas (TCGA)). Of 336 genes associated with fatty acid metabolism in the Gene Ontology database (GO:0006631), we found that 244 (73%) were significantly dysregulated (false-discovery rate (FDR) < 0.05) in triple-negative (TN) versus RP breast tumors (Supplementary Table 2 ). We also found that TN tumors showed upregulation of many genes that encode activators of FAO (including the gene encoding the master transcriptional regulator PPARG coactivator 1 alpha (also known as PGC-1α; encoded by PPARGC1A)) and downregulation of many genes that encode activators of fatty acid synthesis (FAS) (including fatty acid synthase (FASN) and acetyl-coA carboxylase beta (ACACB; also known as ACC2)) (Supplementary Table 2 ). We applied the fatty acid metabolism signature identified from TCGA samples ( Fig. 2a ) to four additional breast cancer clinical cohorts (2,119 total patients including those from TCGA) and confirmed that this signature was highly correlated with TNBC tumor samples ( Supplementary Fig. 2 and Supplementary Table 3 ) [10] [11] [12] [13] . Next we confirmed upregulation of key FAO activators and downregulation of key FAS activators at the protein level in TN versus RP In c, a two-tailed unpaired t-test was used to compare non-tumor to tumor samples. In a,b, all differential metabolite-abundance analyses were performed using the 'limma' R package. *P < 0.05, **P < 0.01, ****P < 0.0001. human breast cancer cell lines ( Fig. 2b) 4, 14, 15 . Notably, whereas FASN and ACC2 were markedly downregulated in TN cell lines as compared to RP cells, ACACA (ACC1) was expressed equivalently in TN and RP cell lines. To directly test whether FAO is increased in MYC high TNBC cells, we measured [ 14 C]oleic acid conversion to 14 CO 2 and found an ~50% increase in FAO in MYC high TNBC cells as compared to MYC low TNBC cells or to RP cells ( Fig. 2c) . Taken together, these data suggest that FAO is upregulated in MYC high TNBC cells.
RP
TNBC is the most aggressive subtype of breast cancer and is characterized by poor clinical outcome 1,2 . To determine whether FAO gene expression is associated with prognosis, we performed univariate analysis of the 336 fatty acid metabolism genes on a patient cohort with long-term distant recurrence-free survival data (Supplementary Table 4 ) 11 . We found that decreased expression of ACACB-which encodes the ACC2 enzyme that produces malonyl-CoA to directly inhibit CPT1A and CPT1B, and therefore FAO-was associated with worse prognosis for all patients, as well as for the TNBC cohort ( Fig. 2d) 9 . Although decreased ACACB expression was also associated with worse outcome for patients with RP tumors, the median time to distant recurrence-free survival was not reached in this cohort, suggesting that FAO may be a less important marker of tumor recurrence in RP cancers (Fig. 2d) . These patient data suggest that decreased ACACB expression, and thus increased FAO, may contribute to the aggressiveness of breast tumors, with the worst outcome occurring in the TNBC subset.
FAO is the primary bioenergetic pathway in many non-tumor tissues 9 . We therefore investigated whether this pathway is essential for energy production in MYC-overexpressing TNBC. We used etomoxir (a clinically tested, specific inhibitor of CPT1) 16 to determine the effects of FAO inhibition on ATP and NAD(P)H production. We first examined nine human breast cancer cell lines (six TN and three RP) with various levels of MYC expression 15 . Etomoxir treatment dramatically inhibited ATP production in TNBC cell lines expressing high amounts of MYC, whereas TN and RP cell lines expressing low amounts of MYC were significantly less affected ( Fig. 3) . Analysis of cell proliferation and apoptosis revealed that etomoxir-treated MYC high cells show decreased proliferation without a decrease in viability ( Supplementary Fig. 3 and Supplementary Data).
To validate the requirement for FAO in MYC-overexpressing TNBC, we used an orthogonal approach in which we extracted data from the Project Achilles data set 17 for the knockdown of CPT1B. Specifically, the growth of 216 cancer cell lines was measured after each line was treated independently with five shRNAs specific for CPT1B 17 . To determine whether CPT1B expression was required for breast cancer growth, we focused on the 13 breast cancer cell lines tested (of which there was no overlap with the lines used above): BT20, CAL120, CAL51, HCC1187, HCC1395, HCC70, MDAMB453, BT474, EFM19, HCC1954, HCC2218, MCF7 and ZR7530. We categorized these lines as RP, TN MYC low and TN MYC high (as in Fig. 3a ) on the basis of MYC expression levels (data not shown). We found that the growth of TN MYC high cells was significantly more sensitive to CPT1B knockdown than that of RP or TN MYC low cells (Fig. 3b) . Additionally, we used siRNA to deplete CPT2, which encodes another essential FAO enzyme 9 . CPT2 knockdown markedly decreased proliferation In b, all differential metabolite abundance analyses were performed using the limma R package. Unless otherwise specified, values shown are mean ± s.e.m. In d-f, tumor volume is shown relative to tumor volume on day 1 of treatment. A two-tailed unpaired t-test was used to compare experimental groups (c-g); ^P ≤ 0.10, *P ≤ 0.05, **P < 0.01, ***P < 0.001; n.s., not significant.
of MYC high TN cells, but it had a significantly weaker growth inhibitory effect on RP cells ( Fig. 3c and Supplementary Fig. 4) . Thus, the results obtained with small-molecule inhibition or with knockdown of CPT1B, as well as with knockdown of CPT2, suggest that FAO is an essential metabolic pathway in MYC-overexpressing TNBC cells.
FAO has been shown to be important for cells that have become detached from matrix and that are grown in nutrient-deprived conditions 18, 19 . We therefore asked whether TN receptor and MYC status affect the response to FAO inhibition for tumor cells that are either not attached to matrix or deprived of glucose. To model matrix detachment, we used ultra-low-adhesion plates and grew breast cancer cell lines as spheres. Whereas TN MYC high , TN MYC low and RP cells were all able to form viable spheres upon matrix detachment, TN MYC high cells were significantly (P < 0.0001) more sensitive to FAO inhibition (Supplementary Fig. 5 ). Next we tested the additive effect of FAO inhibition and glucose deprivation. Both TN MYC high and TN MYC low cells showed an increased sensitivity to glucose deprivation, as compared to that for RP cells (Supplementary Fig. 6) , consistent with the well-established dependence on glycolysis for TNBC cell growth 20 . Concurrent depletion of glucose and inhibition of FAO resulted in an additive effect on ATP depletion in TN, but not in RP, Fig. 6 ). These results are consistent with previous findings that FAO is important for breast cancer cell survival and NADPH production, for conditions of limited glycolysis 21 , and suggest that TN MYC high cells are more reliant on FAO for survival than MYC low cells under conditions of matrix detachment or nutrient deprivation.
cells (Supplementary
To confirm that the observed bioenergetic reliance for FAO in MYC-overexpressing TNBC cells is a MYC-dependent phenotype, we examined whether conditional MYC expression alters the sensitivity of cells to FAO inhibition. We used two approaches; the first was to use non-tumor human mammary epithelial (HMEC) cells expressing a 4-hydroxytamoxifen (TAM)-inducible MYC-estrogen receptor (ER) fusion protein (hereafter referred to as HMEC MYC-ER cells), and the second was to use two RP lines, each stably transduced with a MYC overexpression construct or control vector 1, 15 (Supplementary Fig. 7) . TAM-induced HMEC MYC-ER and MYC-transduced RP cells were significantly more sensitive to etomoxir than uninduced HMEC MYC-ER and vector-transduced RP cells, respectively (Fig. 3d) . Furthermore, siRNA-mediated knockdown of MYC significantly rescued etomoxir sensitivity in three of four MYC high TNBC cell lines tested ( Fig. 3e and  Supplementary Fig. 8 ). Finally, MYC protein expression significantly (Fig. 3f) . Although MYC expression was not tightly correlated with FAO or FAS protein expression ( Figs. 2b  and 3f) , it did correlate well with FAO-inhibition sensitivity and FAO activity ( Figs. 2c and 3f) . These data suggest that MYC expression is both necessary and sufficient to induce a bioenergetic reliance for FAO in breast epithelial and breast cancer cells. Given that our initial observation of dysregulated FAO was made in MYC-driven breast tumors, we sought to test the effects of FAO inhibition on the metabolism of MYC-overexpressing TNBC in vivo. We obtained a panel of human TN and RP breast cancer patientderived xenografts (PDX) with various MYC levels (Fig. 4a) 22 . We administered etomoxir (60 mg per kg of body weight (mg/kg)) or vehicle by i.p. injection to mice bearing orthotopic HCI-002 MYC high TNBC PDXs at two time points (0 and 24 h) ( Fig. 4a) 22 . Metabolite analysis of HCI-002 tumors harvested at 26 h revealed a significant reduction in long-chain acylcarnitine levels, as well as a reduction in TCA cycle intermediates (especially α-ketoglutarate) in drugtreated tumors, as compared to vehicle-treated tumors ( Fig. 4b and Supplementary Table 5 ). Etomoxir-treated tumors had a significant increase in phosphorylated AMPK (pAMPK) levels, a well-established marker of bioenergetic stress, as compared to control-treated tumors (Fig. 4c) . In a second metabolomic study, as compared to vehicletreated tumors, MTB-TOM tumors that were treated with 20 mg/kg etoxomir for 14 d showed a marked reduction in the levels of the majority of TCA cycle intermediates measured, as well as in the level of ATP, and also showed a significant (P < 0.05) increase in AMP/ATP, ADP/ATP, UMP/UTP and UDP/UTP ratios ( Supplementary Fig. 9 and Supplementary Table 6 ). These data indicate that treatment with an FAO inhibitor decreases bioenergetic metabolism in vivo in both transgenic and PDX models of TNBC.
This observed reduction in bioenergetic metabolism prompted us to analyze the effects of prolonged FAO inhibition on the growth of MYCoverexpressing TNBC tumors. We performed orthotopic transfer of MTB-TOM or HCI-002 PDX tumors into the mammary fat pad of syngeneic FVB/N or immunodeficient NOD/SCID mice, respectively. In the case of MTB-TOM allograft-bearing mice, we administered 40 mg/kg etomoxir or vehicle by i.p. injection daily for 14 d; in the case of HCI-002 PDX-bearing mice, we administered 40 or 60 mg/kg etomoxir or vehicle by i.p. injection daily for 21 d. Etomoxir treatment resulted in a significant attenuation of tumor growth in both models and a significant extension of the time to ethical end point in the PDX model ( Fig. 4d,e) . In contrast, we observed no significant attenuation in tumor growth of mice with HCI-009 MYC low TNBC PDX tumors that were treated with 40 mg/kg etomoxir (Fig. 4f) . HCI-009 showed a moderate level of ACC2 expression ( Fig. 4a) , suggesting that FAO might be attenuated in these tumors and explaining their resistance to etomoxir. The efficacy of etoxomir in both MYC high transgenic and PDX models, but not in a MYC low PDX model, suggests that high MYC expression, as well as low ACC2 expression, may serve as a biomarker of sensitivity to FAO inhibition.
Next we determined the effects of FAO inhibition on cell proliferation and death. HCI-002 PDX-bearing mice that were treated with 60 mg/kg etomoxir showed significantly decreased staining of the cell proliferation marker Ki-67 in the tumors (indicative of decreased cell proliferation), as compared to tumors from vehicle-treated mice, and a dose-dependent increase in TUNEL staining (indicative of increased apoptosis) (Fig. 4g,h) . In contrast, etomoxir treatment of cultured MYC-overexpressing TNBC cell lines had a marked effect on cell proliferation but no appreciable effects on cell death (Supplementary Fig. 3) .
These contrasting results suggest that FAO has a more critical role for in vivo tumor cell viability than it does in vitro.
Elevated MYC expression was recently discovered to be a defining factor of TNBC 1, 2 . The present study is among the first to investigate the role of MYC in TNBC metabolism in vivo 20 . Here we show that FAO is upregulated in MYC-overexpressing TNBC cells and that TNBC is sensitive to FAO inhibition in a MYC-dependent manner, as shown using several models of MYC-overexpressing TNBC in vitro and PDX and transgenic models in vivo. This work supports a critical role for FAO in TNBC, and it identifies high levels of MYC expression as a marker for this dependence. On the basis of our findings, inhibition of FAO as a therapeutic strategy for MYC-overexpressing TNBC should be further investigated.
METHOds
Methods and any associated references are available in the online version of the paper. 
ONLINE METHOds
Patient-derived xenograft models. All human samples used to generate PDX tumors, as well as the human non-tumor samples, were previously described 22 .
MTB-TOM tumor generation. All protocols described in this and other sections regarding animal studies were approved by the UCSF Institutional Animal Care and Use Committee. MTB-TOM (MMTV-rtTA/TetO-MYC) mice were generated as previously described 5 . Mice were bred and maintained off of doxycycline. At 12-15 weeks of age, female mice were put on doxycycline (200 mg/kg doxy chow, Bio-Serv) to induce MYC expression and tumorigenesis. Mice were monitored daily for tumor growth by inspection and caliper measurement in two dimensions. Mice were sacrificed as per ethical guidelines (tumors reaching 2 cm in any single dimension) and tumor(s) or mammary gland(s) were flash-frozen in liquid nitrogen.
Metabolomics. For U-[ 13 C]palmitate flux analyses, the labeled palmitate (Cambridge Isotope Laboratories Inc., CLM-409-0.5) or unlabeled palmitate (Sigma) was diluted in PEG40 (Spectrum) via sonication and was administered via intraperitoneal injection at 100 mg/kg. 4 h after the injection, the animals were sacrificed and the tumors were flash-frozen.
Nonpolar metabolites were extracted using a Dounce homogenizer in 4 ml of 2:1:1 chloroform:methanol:PBS spiked with 10 nmol of internal standards (C12:0 dodecylglycerol and pentadecanoic acid; Sigma). Separation of organic and aqueous layers was achieved via centrifugation at 1,000g for 5 min at 4 °C. Secondary extraction of the aqueous layer was performed using 0.1% formic acid followed by addition of 2 ml chloroform and further centrifugation. After combining the organic extractions, the lipid-containing mixture was dried under nitrogen (N 2 ) and dissolved in 120 µl chloroform. Single-reaction monitoring (SRM) liquid chromatography-coupled to tandem mass spectrometry (LC-MS/ MS)-on an Agilent 6400 series QQQ using 10 µl of sample-was achieved using a reverse-phase C5 column (Phenomenex, Luna 50 mm × 4.6 mm, 5-µm particle diameter). Mobile phases were buffer A (composed of 95:5 water:methanol) and buffer B (60:35:5 2-propanol:methanol:water). Solvent modifiers were 0.1% formic acid with 5 mM ammonium formate or 0.1% ammonium hydroxide for positive and negative ionization modes, respectively.
For polar metabolites, frozen tissue was homogenized using a TissueLyser in 300 µl of 40:40:20 acetonitrile:methanol:water with the addition of 1 nM (final concentration) of D3-[ 15 N]serine as an internal extraction standard (Cambridge Isotopes Laboratories Inc, DNLM-6863). 10 µl of cleared supernatant (via centrifugation at 15,000 r.p.m., 10 min, at 4 °C) was used for SRM-LC-MS/MS using a normal-phase Luna NH 2 column (Phenomenex). Mobile phases were buffer A (composed of 100% acetonitrile) and buffer B (composed of 95:5 water: acetonitrile). Solvent modifiers were 0.1% formic acid or 0.2% ammonium hydroxide with 50 mM ammonium acetate for positive and negative ionization modes, respectively.
All metabolites were analyzed using the MassHunter software package (Agilent Technologies) by quantifying the transition from parent precursor mass to product ions for each individual metabolite.
Gene expression analysis.
TCGA breast-invasive carcinoma data set was sourced from data generated by TCGA Research Network (http://cancergenome.nih.gov), made available on the University of California, Santa Cruz (UCSC) Cancer Browser. Series matrix files for ISPY1 (accession code GSE22226) and a neoadjuvant chemotherapy-treated cohort (accession code GSE25066) were downloaded from the Gene Expression Omnibus (GEO) site and processed using the GEOquery R package 10, 11, 23 . A chemotherapy-naive cohort and an aggressively treated early-stage cohort were obtained from the UCSC Cancer Browser 12, 13 . Multiple probes corresponding to the same gene were collapsed using the 'MaxMean' method in the weighted correlation network analysis (WGCNA) R package 24, 25 .
A fatty acid metabolism gene set was compiled using genes containing the Gene Ontology term, GO:0006631 (http://geneontology.org). An average expression profile (centroid) of these genes was calculated for the triplenegative subset of samples within the breast-invasive carcinoma data set from TCGA. Similarities between this centroid and the gene expression profiles of samples from the four independent clinical cohorts were then quantified using a Pearson correlation metric.
Heat maps and clustering analyses were performed using the 'gplots' (http://cran.r-project.org/web/packages/gplots/index.html) and 'cluster' (http:// cran.r-project.org/web/packages/cluster/index.html) R packages respectively.
To generate Kaplan-Meier plots, samples were grouped by receptor status and dichotomized by ACC2 expression at an optimal threshold, yielding groups with the most significant difference in distant recurrence-free survival based on the log-rank test. Kaplan-Meier plots were then generated for the respective groups using the 'survival' (http://cran.r-project.org/web/packages/survival/ index.html) R package.
Univariate Cox proportional-hazards regression analysis was performed using the 'survival' R package to assess the correlation of fatty acid metabolism gene expression to distant recurrence-free survival in the pooled neoadjuvant chemotherapy-treated cohort 11 . This was conducted for all tumors, TN tumors and RP tumors.
triplicate. Cells were incubated in serum-free medium for 2 h and then incubated in standard medium for 1 h. [ 14 C]oleic acid (Moravek Biochemicals, MC406) at 0.1 µCi/µl was added, 2 × 2 cm squares of Whatman paper were taped over the wells, and the cells were incubated for 3 h at 37 °C. After adding 200 µl 3 M NaOH directly to each square of Whatman paper, 100 µl 70% perchloric acid was added to each well and CO 2 was captured at room temperature for 1 h. The Whatman paper was dried at room temperature and placed in a scintillation vial with 5 ml scintillation fluid. 14 C radioactivity was measured using a liquid scintillation counter and normalized to protein concentration.
RNAi knockdown. MYC-specific (L-003282-02-0005), CPT2-specific (M-008574-01-005) and nontargeting (D-001810-10-20) siRNAs were purchased from GE Dharmacon (SMARTpool, four siRNAs per gene). 30 pmol siRNA was used to transfect cells with the Lipofectamine RNAiMAX Transfection Reagent (Life Technologies), according to the manufacturer's instructions. Cells were incubated with siRNA for 72 h. For siMYC studies, medium was changed at 24 h, and 0 and 200 µM etomoxir was added for 48 h before ATP levels were quantified as described above. For siCPT2 studies, the relative number of cells was determined at 72 h as described below.
The CPT1-knockdown data was extracted from the Project Achilles data set 17 . The viability score represents the ATARiS solution, which is the computationally derived score that quantifies the gain or loss of growth specific to knockdown of the gene from pooled shRNA screens.
Proliferation and viability assays.
To determine the effects of etomoxir treatment on cell proliferation, cells were seeded in 6-well plates at 100,000-150,000 cells/well and cultured in the presence of 0 or 200 µM etomoxir. Cells were harvested at 24, 48 and 72 h. Cell counts were determined using the Countess Automated Cell Counter (Life Technologies) according to the manufacturer's instructions. Cell viability was assessed by performing the flow cytometrybased Guava ViaCount viability assay (Millipore) according to the manufacturer's instructions. To determine the effects of siCPT2 treatment on cell proliferation, cells were seeded in 6-well plates at 100,000-150,000 cells per well and transfected with siNT or siCPT2 as described above. Cells were harvested at 24, 48 and 72 h, and cell counts were determined using the Countess Automated Cell Counter (Life Technologies) according to the manufacturer's instructions. Three independent biological replicates were performed for each time point and condition.
Matrix detachment assays.
To determine the effects of matrix detachment, cells were seeded in ultra-low adhesion round-bottom 96-well plates at 1,000 cells/well. Sphere formation was judged by bright-field imaging 4 d after seeding, and then spheres were subsequently cultured in 0 or 200 µM etomoxir for 48 h, with triplicate samples for each condition. Relative ATP concentrations were determined as described above.
Glucose-starvation assays. To determine the effects of glucose starvation, cells were seeded in 96-well plates at 5,000-7,000 cells/well and cultured in replete medium, glucose-depleted medium, 200 µM etomoxir or glucose-depleted medium with 200 µM etomoxir for 24 h, with triplicate samples for each condition. Relative ATP concentration was determined as described above.
Orthotopic allograft and xenograft studies. 4-week-old WT FVB/N and immunocompromised NOD/SCID female mice were purchased from Taconic Biosciences. The derivation of HCI-002 and HCI-009 TN patient-derived xenograft tumors has been previously described 22 . Viably frozen MTB-TOM, HCI-002 and HCI-009 tumor samples were transplanted into the cleared mammary fat pads of FVB/N and NOD/SCID mice, respectively. Tumor growth was monitored daily by caliper measurement in two dimensions. Researchers were not blinded to the treatment groups.
For the [ 13 C]palmitate experiment (Fig. 1c) , tumors were allowed to reach ~1.5 cm 3 , and then the mice were randomized into experimental groups. Mice received 100 mg/kg [ 12 C]palmitate or [ 13 C]palmitate, delivered by i.p. injection at t = 0 h. The palmitate solution was prepared by sonication into PEG-40 (Spectrum). Mice were euthanized at t = 4 h, following which tumors and contralateral non-tumor mammary glands were flash-frozen in liquid nitrogen.
For the HCI-002 acute etomoxir-treatment experiment (Fig. 4b) , tumors were allowed to reach ~1.5 cm 3 , and mice were then randomized into experimental groups. Mice received vehicle or 60 mg/kg etomoxir, delivered by i.p. injection, at t = 0 and 24 h. Mice were euthanized at t = 26 h, and the tumors were flash-frozen in liquid nitrogen.
For the remaining in vivo studies, tumors were allowed to reach ~1 cm 3 ; mice were then randomized into experimental groups, and drug treatment was initiated. For the MTB-TOM studies (Fig. 4d, Supplementary Fig. 9 and Supplementary Table 6 ), mice received vehicle or 20 or 40 mg/kg etomoxir, delivered by i.p. injection, daily for 14 d. Tumor growth was monitored daily by caliper measurement. Mice were euthanized after 14 d of treatment or after tumors reached 2 cm in any dimension, following which the tumors were flashfrozen in liquid nitrogen. For the HCI-002 and HCI-009 studies (Fig. 4e,f) , mice received vehicle, 40 or 60 mg/kg etomoxir, delivered by i.p. injection, daily for 21 d. Tumor growth was monitored daily by caliper measurement. Mice were euthanized after 21 d of treatment or after tumors reached 2 cm in any dimension; for the HCI-002 study, two pieces of tumor from separate locations were fixed in 4% paraformaldehyde (n = 5 for vehicle; n = 7 for 40 mg/kg; n = 4 for 60 mg/kg). The remaining tumor tissue was flash-frozen in liquid nitrogen.
Immunohistochemical analysis. PFA-fixed tumor samples were paraffinembedded, and a tissue microarray of HCI-002 tumors was created using two 2-mm punch cores per tumor. Immunohistochemical staining of tissue microarrays for Ki-67 was performed using the MIB-1 antibody clone (1:50 dilution; DAKO, Carpinteria, CA, USA), after 20 min of antigen retrieval with epitope-retrieval solution 2 (Leica Biosystems, Buffalo Grove, IL, USA). Images were scored as the percentage of Ki-67 + tumor cell nuclei per total tumor cell nuclei in each captured field using Immunoratio software (http:// jvsmicroscope.uta.fi/immunoratio/). TUNEL staining was performed using the ApopTag Peroxidase In situ Apoptosis Detection Kit (Millipore) according to the manufacturer's instructions. Images were scored as the total number of TUNEL + cells per captured field. All quantification was performed in a fashion that was blinded to treatment group.
Statistical analysis.
Prism software was used to generate and analyze Pearson correlations ( Fig. 3f ) and the survival plot ( Fig. 4e) . Correlation P values were generated using a two-sided t-test. Clade-enrichment P value was generated using a Fisher's exact test. Survival plot P value was generated using a log-rank test. All differential metabolite abundance and gene expression analyses were performed using the 'limma' R package.
Differential metabolite abundance between MTB-TOM tumors and non-tumor mammary glands was performed using the limma R package 29 . Metabolites that were significantly different between these groups at a falsediscovery rate of 0.05 were extracted for downstream analyses. Pathway enrichment within this set of metabolites was quantified using the 'MaxMean' method within the 'piano' R package 30 , based on annotations from the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). Significantly enriched pathways were identified at a P value cutoff of 0.05.
For all other comparisons, unpaired two-sided t-tests were used (GraphPad). No statistical method was used to predetermine sample size. The investigators were not blinded to allocation for the in vivo experiments. The investigators were blinded to allocation for immunohistochemical analyses. For all in vivo studies, mice were randomized to treatment groups when tumors reached a predetermined volume on a per experiment basis, as described above. For each data set, the data meet the assumptions of the statistical test used, as determined by distribution and variance.
The sample size for all experiments (in vitro and in vivo) was not chosen with consideration of adequate power to detect a prespecified effect size. For in vitro studies, all completed experiments are reported. For in vivo studies, the number of indicated mice represents the total number of mice treated and processed for each experiment. No samples were fully processed for metabolomic, western blot, or immunohistochemical analysis and then excluded. For the etomoxir-treatment studies, mice were euthanized at the ethical endpoint (~2 cm) or at the study endpoint, unless they failed to meet the predetermined UCSF Institutional Animal Care and Use Committee quality-of-life guidelines. No mice that completed the studies were excluded from analyses. In the prolonged npg
